<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344786</url>
  </required_header>
  <id_info>
    <org_study_id>CNF2024-CLL-05002</org_study_id>
    <secondary_id>120CL101</secondary_id>
    <nct_id>NCT00344786</nct_id>
  </id_info>
  <brief_title>Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL</brief_title>
  <official_title>A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLL dosing escalating study; daily dosing schedule; PK/PD safety
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, open-label, accelerated-titration study designed to evaluate the effects of
      increasing doses of CNF2024 on safety, pharmacokinetics, pharmacodynamic markers, and
      hematological response
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's decision
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toxicity (maximum tolerated dose (MTD))</measure>
    <time_frame>4 week periods until MTD is reached</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Dosing period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine clinical and hematological response</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the recommended Phase 2 dose</measure>
    <time_frame>Study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>B-Cell Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>CNF2024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNF2024 (BIIB021)</intervention_name>
    <description>Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.
Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment.</description>
    <arm_group_label>CNF2024</arm_group_label>
    <other_name>Single arm trial; no comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CLL who relapsed following or are intolerant to purine analog -based
             therapy

          -  Hemoglobin &gt;=9 gm/dL (may be post-transfusion)

          -  Total bilirubin &lt;2 X ULN, and ALT and AST &lt;2 x ULN

          -  Creatinine &lt;=2 X ULN

          -  Normal plasma cortisol and ACTH concentrations

          -  ECOG Performance Status &lt;=2

          -  Anticipated survival &gt;=3 months

          -  For men and women of child-producing potential, use of effective contraceptive methods
             during the study and for one month after treatment

          -  Ability to understand the requirements of the study, provide written informed consent
             and authorization of use and disclosure of protected health information, and agree to
             abide by the study restrictions and return for the required assessments

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Treatment with chemotherapy, monoclonal antibody, or radiotherapy within 28 days
             before entering the study

          -  Participation in any investigational drug study within 28 days before CNF2024
             administration

          -  Patients with secondary malignancy requiring active treatment (except hormonal
             therapy)

          -  Active symptomatic bacterial, fungal, or viral infection including active HIV or viral
             (A, B, or C) hepatitis

          -  Problems with swallowing or malabsorption

          -  Diarrhea (excess of 2-3 stools/day above normal frequency in the past month)

          -  Gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or
             hemorrhagic coloproctitis

          -  Major surgery of the stomach or small intestine

          -  Adrenal dysfunction

          -  Patients with life- or function-threatening CLL complications (e.g., cord compression,
             hemolytic crisis, urinary tract obstruction)

          -  Any illness or condition that in the opinion of the investigator may affect safety of
             treatment or evaluation of any the study's endpoints
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Storgard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2006</study_first_submitted>
  <study_first_submitted_qc>June 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <last_update_submitted>June 4, 2009</last_update_submitted>
  <last_update_submitted_qc>June 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>CNF2024</keyword>
  <keyword>Hsp90 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

